For immunochemical detection of VcMMAE-labeled antibodies
Related Products
Alternative(s)
44706MMAE Monoclonal Antibody (Clone 1G1)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

VcMMAE Polyclonal Antibody - Biotinylated

Item No. 42295

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • VC-MMAE
  • VC-Monomethyl Auristatin E Conjugate
Immunogen
VcMMAE-KLH conjugate
Formulation (Request formulation change)
200 µg of protein A-affinity purified polyclonal antibody
Storage Buffer
PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide
Host
Rabbit
Applications
ELISA
Cross Reactivity
(+) VcMMAE-labeled antibodies(-) Albumin(-) Unlabeled antibodies
Species Reactivity
(Independent) Species
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    200 µg

    $439

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    VcMMAE is a drug-linker molecule that has been used in the synthesis of antibody-drug conjugates (ADCs).1,2 It contains maleimide, the cathepsin B substrate valine-citrulline (Val-Cit) dipeptide, and p-aminobenzyl carbamate (PABC) conjugated to the antimitotic agent monomethyl auristatin E (MMAE).1 The maleimide in VcMMAE allows it to be conjugated to cysteine residues in antibodies, which target the ADC to specific cell types. Once inside the cell, the Val-Cit dipeptide is cleaved by cathepsin B and MMAE is released.3,1 Formulations containing VcMMAE have been used in the treatment of diffuse large B cell lymphoma (DLBCL), Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and urothelial cancer. Cayman’s VcMMAE Polyclonal Antibody can be used in ELISA for the detection of ADCs containing the VcMMAE linker.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Chuprakov, S., Ogunkoya, A.O., Barfield, R.M., et al. Tandem-cleavage linkers improve the in vivo stability and tolerability of antibody-drug conjugates. Bioconjug. Chem. 32(4), 746-754 (2021).

    2. Dimou, M., Papageorgiou, S.G.S., N., Katodritou, E., et al. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Hematol. Oncol. 39(3), 336-348 (2021).

    3. Yao, H., Jiang, F., Lu, A., et al. Methods to design and synthesize antibody-drug conjugates (ADCs). Int. J. Mol. Sci. 17(2), 194 (2016).